naltrexone has been researched along with docetaxel anhydrous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aoyagi, K; Ashikawa, M; Chiwaki, F; Fujita, T; Fukagawa, T; Katai, H; Komatsu, M; Kushima, R; Nagase, H; Nakagama, H; Narita, M; Sakamoto, H; Sasaki, H; Sawada, Y; Suzuki, M; Suzuki, T; Uezono, Y; Yanagihara, K; Yoshida, T | 1 |
1 review(s) available for naltrexone and docetaxel anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for naltrexone and docetaxel anhydrous
| Article | Year |
|---|---|
Peripheral opioid antagonist enhances the effect of anti-tumor drug by blocking a cell growth-suppressive pathway in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Proliferation; Docetaxel; Drug Synergism; Growth Inhibitors; Humans; Mice; Naltrexone; Narcotic Antagonists; Quaternary Ammonium Compounds; Receptors, Opioid; Stomach Neoplasms; Taxoids | 2015 |